Deborah H. Charych

CIK: 0001965700

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

SKYE

Skye Bioscience, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (4 total)

SKYE
Skye Bioscience, Inc.
Mar 31, 2026
Award(A)
Stock Option (Right to Buy)
Direct
75K shares-
SKYE
Skye Bioscience, Inc.
Feb 6, 2026
Award(A)
Stock Option (Right to Buy)
Direct
35K shares-
SKYE
Skye Bioscience, Inc.
Feb 24, 2025
Award(A)
Stock Option (Right to Buy)
Direct
35K shares-
SKYE
Skye Bioscience, Inc.
Oct 28, 2024
Award(A)
Stock Option (Right to Buy)
Direct
70K shares-

		Type	Shares	Price		Ownership
Mar 31, 2026	SKYE Skye Bioscience, Inc.	Award(A) Stock Option (Right to Buy)	75,000	-	-	Direct
Feb 6, 2026	SKYE Skye Bioscience, Inc.	Award(A) Stock Option (Right to Buy)	35,000	-	-	Direct
Feb 24, 2025	SKYE Skye Bioscience, Inc.	Award(A) Stock Option (Right to Buy)	35,000	-	-	Direct
Oct 28, 2024	SKYE Skye Bioscience, Inc.	Award(A) Stock Option (Right to Buy)	70,000	-	-	Direct

1-4 of 4 transactions

About Charych Deborah H.

Charych Deborah H. (SEC CIK 0001965700) files insider reports with the SEC as Director of Skye Bioscience, Inc. (SKYE).

Signal8 holds 4 ownership filings by Charych Deborah H., all Form 4s, filed between Oct 30, 2024 and Apr 2, 2026. Those filings report 4 transactions, from Oct 28, 2024 to Mar 31, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Charych Deborah H.'s filings is in SAN DIEGO, CA.

Recent filings by Charych Deborah H.

Mar 31, 2026: Grant or award of SKYE derivative securities (Form 4, code A).
Feb 6, 2026: Grant or award of SKYE derivative securities (Form 4, code A).
Feb 24, 2025: Grant or award of SKYE derivative securities (Form 4, code A).
Oct 28, 2024: Grant or award of SKYE derivative securities (Form 4, code A).

Other insiders filing for Skye Bioscience, Inc. (SKYE)

Schwab Andrew J., Director
5AM Partners VII, LLC, 10% Owner
DHILLON PUNIT, Chief Executive Officer
Sharp John P, Chief Financial Officer
Smith Karen L., Director
Twitty Christopher, Chief Scientific Officer

How to read Form 4 transaction codes